Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated
Your view on LGND
Overview
What the company does, where it operates, and who runs it.
About Ligand Pharmaceuticals Incorporated
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Todd C. Davis
- Headquarters
- 5980 Horton Street, Jupiter, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Todd C. Davis
- Headquarters
- 5980 Horton Street, Jupiter, CA, US
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.
Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression.
In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension.
The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Ligand Pharmaceuticals Incorporated, and the rating behind it. LGND last traded at $284.47, 28.6× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Ligand Pharmaceuticals Incorporated. Starting points for Ligand Pharmaceuticals Incorporated: P/E 28.6, EPS $9.83, beta 0.98 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Ligand Pharmaceuticals Incorporated. Ligand Pharmaceuticals Incorporated does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Ligand Pharmaceuticals Incorporated. Trailing twelve-month EPS for Ligand Pharmaceuticals Incorporated stands at $9.83. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Ligand Pharmaceuticals Incorporated. Ligand Pharmaceuticals Incorporated has reported as a listed company since 1992. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Ligand Pharmaceuticals Incorporated valued side by side against its closest peers. Ligand Pharmaceuticals Incorporated is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Ligand Pharmaceuticals Incorporated, and how their positions are changing. At a $5.70B market value, institutional positions materially move Ligand Pharmaceuticals Incorporated's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Ligand Pharmaceuticals Incorporated executives and directors. Shares of Ligand Pharmaceuticals Incorporated have traded between $93.58 and $212.49 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Ligand Pharmaceuticals Incorporated. Ligand Pharmaceuticals Incorporated is a $5.70B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Ligand Pharmaceuticals Incorporated. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Ligand Pharmaceuticals Incorporated. Coverage tracks Ligand Pharmaceuticals Incorporated within Biotechnology (Healthcare). Press releases and market coverage, newest first.